Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on May 18, 2021 6:36pm
184 Views
Post# 33227281

RE:RE:RE:RE:RE:RE:Soleus sold 474,000 before the end of March

RE:RE:RE:RE:RE:RE:Soleus sold 474,000 before the end of MarchI blame folks who found these institutions, structured the deal and approved it. If the clinical trials are successful these institutions would blame themselves, but between now and then these selling are not what we wanted to see when the company eventually is in an inflection point.
qwerty22 wrote:

You can't blame them for being offered the stock cheap. And weren't they accumulating before the offering? What you say might be true but it might be underselling them as well.

 

scarlet1967 wrote: Also I don't think we should be surprised as these institutions participated in a steal deal so they are bargain hunters(penny chasers) so instead of the copycat effect we ended up with investors who offload gradually their positions for a small profit rather than waiting out the clinical outcome of the programs. If it wasn't for the ripple effect of more than few strategic incorrect decisions the valuation would've been been more in line with comps.
I do understand that they still have a sizeable position and I don't anticipate they are selling for any other reason than making some profit so I don't believe this selling has anything to do with the progress of the trial as it was done in March.


 

 

scarlet1967 wrote: I really believe the key to deal with the valuation discrepancies is addinh a retail friendly approach to their marketing efforts.
Get the demand and volume higher first then institutional investors and wealthy retail investors will join the party.
SPCEO1 wrote: There is no indication of other new institutional owners so one has to wonder if the other two purported institutions who participated in the OO have flipped their shares already. That seems unlikely, but no other group with more than 1% of the outstanding shares are listed on Bloomberg besides Soleus, ourselves and the Caisse.
scarlet1967 wrote: As per their 13F yesterday filing Worth Venture partners increased their position from 146162 to 851413 shares and Morgan Stanley increased their position from 403870 shares to 703735 shares.

https://fintel.io/sob/us/thtx

SPCEO1 wrote: They still own nearly 7 million shares as of the end of March but did sell 474,000 between the offering and the end of March. Not sure what, if anything, that might mean but that is what Bloomberg is reporting.

 

 

 

 




<< Previous
Bullboard Posts
Next >>